{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:59:00Z","timestamp":1790391540334,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2016R1A6A1A03011325 and 2016R1D1A1B01009559"],"award-info":[{"award-number":["NRF-2016R1A6A1A03011325 and 2016R1D1A1B01009559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Histone deacetylases (HDACs) have emerged as important therapeutic targets for various diseases, such as cancer and neurological disorders. Although a majority of HDAC inhibitors use hydroxamic acids as zinc binding groups, hydroxamic acid zinc-binding groups suffer from poor bioavailability and nonspecific metal-binding properties, necessitating a new zinc-binding group. Salicylic acid and its derivatives, well-known for their therapeutic value, have also been reported to chelate zinc ions in a bidentate fashion. This drew our attention towards replacing hydroxamic acid with salicylamide as a zinc-binding group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In this study, for the first time, compound\n                      <jats:bold>5<\/jats:bold>\n                      possessing a novel salicylamide zinc-binding group was synthesized and evaluated biologically for its ability to inhibit various HDAC isoforms and induce acetylation upon \u03b1-tubulin and histone H3 among MDA-MB-231 cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Compound\n                      <jats:bold>5<\/jats:bold>\n                      exhibits selective inhibition against class I HDAC isoforms (HDAC1, 2, and 3) over class II and IV HDAC isoforms (HDAC4, 6, and 11). The exposure of MDA-MB-231 cells to compound\n                      <jats:bold>5<\/jats:bold>\n                      efficiently induced the acetylation of more histone H3 than \u03b1-tubulin, suggesting that compound\n                      <jats:bold>5<\/jats:bold>\n                      is a class I selective HDAC inhibitor. Moreover, the molecular docking study indicated that the salicylamide zinc-binding group of compound\n                      <jats:bold>5<\/jats:bold>\n                      coordinates the active zinc ion of class I HDAC2 in a bidentate fashion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Overall, salicylamide represents a novel zinc-binding group for the development of class I selective HDAC inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract:<\/jats:title>\n                    <jats:p>(http:\/\/links.lww.com\/MD\/G668)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000029049","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T15:01:03Z","timestamp":1651762863000},"page":"e29049","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group"],"prefix":"10.1097","volume":"101","author":[{"given":"Ji Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan Hashim","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Jin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-8761","authenticated-orcid":false,"given":"Young Ho","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.bbapap.2016.06.007","article-title":"The world of protein acetylation","volume":"1864","author":"Drazic","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s12272-018-1045-z","article-title":"Aspirin-inspired acetyl-donating HDACs inhibitors","volume":"41","author":"Lim","year":"2018","journal-title":"Arch Pharm Res"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12272-012-0221-9","article-title":"Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery","volume":"35","author":"Seo","year":"2012","journal-title":"Arch Pharm Res"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-019-49784-9","article-title":"Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-beta probes","volume":"9","author":"Choi","year":"2019","journal-title":"Sci Rep"},{"key":"R7-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246213","article-title":"Development of thiazolidinedione-based HDAC6 inhibitors to overcome methamphetamine addiction","volume":"20","author":"Sharma","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R8-20250504","first-page":"460","article-title":"Histone deacetylase inhibitors differentially regulate c-Myc expression in retinoblastoma cells","volume":"19","author":"Yu","year":"2020","journal-title":"Oncol Lett"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3892\/ol.2020.11587","article-title":"Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors","volume":"20","author":"Bobrowicz","year":"2020","journal-title":"Oncol Lett"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"R13-20250504","first-page":"84","article-title":"Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejmech.2017.12.061","article-title":"Development of novel beta-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells","volume":"144","author":"Ling","year":"2018","journal-title":"Eur J Med Chem"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2017.03.069","article-title":"Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: design, structure-activity relationship and anti-tumor activity study","volume":"134","author":"Li","year":"2017","journal-title":"Eur J Med Chem"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejmech.2017.03.079","article-title":"4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo","volume":"134","author":"Mehndiratta","year":"2017","journal-title":"Eur J Med Chem"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1021\/jm00394a032","article-title":"In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase","volume":"30","author":"Summers","year":"1987","journal-title":"J Med Chem"},{"issue":"(10 pt 1)","key":"R19-20250504","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R20-20250504","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0317","article-title":"From plant extract to molecular panacea: a commentary on Stone (1763) \u2019An account of the success of the bark of the willow in the cure of the agues\u2019","volume":"370","author":"Wood","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/182741a0","article-title":"Stability of metal complexes with salicylic acid and related substances","volume":"182","author":"Perrin","year":"1958","journal-title":"Nature"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhazmat.2011.05.050","article-title":"Efficient removal of heavy metal ions from aqueous solution using salicylic acid type chelate adsorbent","volume":"192","author":"An","year":"2011","journal-title":"J Hazard Mater"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jps.2600500202","article-title":"Role of metal-binding in the biological activities of drugs","volume":"50","author":"Foye","year":"1961","journal-title":"J Pharm Sci"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"111563","DOI":"10.1016\/j.ejmech.2019.111563","article-title":"Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors","volume":"181","author":"Chen","year":"2019","journal-title":"Eur J Med Chem"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/anie.201101317","article-title":"Highly selective fluorescent probe for vicinal-dithiol-containing proteins and in situ imaging in living cells","volume":"50","author":"Huang","year":"2011","journal-title":"Angew Chem Int Ed Engl"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejmech.2019.05.089","article-title":"Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy","volume":"178","author":"Yang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejmech.2018.12.056","article-title":"A novel class of anthraquinone-based HDAC6 inhibitors","volume":"164","author":"Song","year":"2019","journal-title":"Eur J Med Chem"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1073\/pnas.1900441116","article-title":"Effects of alpha-tubulin acetylation on microtubule structure and stability","volume":"116","author":"Eshun-Wilson","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-20250504","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.00256","article-title":"Synthesis and biological evaluation of HDAC inhibitors with a novel zinc binding Group","volume":"8","author":"He","year":"2020","journal-title":"Front Chem"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1568026619666190122144949","article-title":"Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups","volume":"19","author":"Li","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"e0139523","DOI":"10.1371\/journal.pone.0139523","article-title":"Breast cancer cell line aggregate morphology does not predict invasive capacity","volume":"10","author":"Ziperstein","year":"2015","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:14:23Z","timestamp":1746314063000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":31,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029049","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"2021-09-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}